EUVIMEDEUVIMED entdecken
Crossref

Projected Global Clinical, Humanistic, and Economic Impact of Metabolic Dysfunction-Associated Steatohepatitis (MASH): The Cost of Inaction Based on Data From Nine Countries

Zobair M Younossi, James M Paik, Jeffrey V Lazarus, Patrizia Burra, Yuichiro Eguchi, Frank Tacke, Javier Crespo, Cristiane A Villela-Nogueira, Paul N Brennan, Hussain Abdulrahman Al-Omar, Manuel Romero-Gomez, Cyrielle Caussy und 31 weitere

Clinical Gastroenterology and Hepatology · 2026-04 · 24 (4) · 1016-1034

DOI: 10.1016/j.cgh.2025.09.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-04. Verfasst von Zobair M Younossi und 42 weiteren Autor:innen. Beteiligte Einrichtung: The Global NASH/MASH Council, Washington, DC; Beatty Liver and Obesity Research Program, Inova Health System, Falls Church, Virginia; Center for Outc…. Hauptthemen laut MEDLINE: Metabolic Diseases, Fatty Liver, Global Burden of Disease, Health Care Costs. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Boehringer Ingelheim, Madrigal Pharmaceuticals Inc, Novo Nordisk AS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Although the clinical burden of metabolic dysfunction-associated steatohepatitis (MASH) is well-known, its economic burden is less well-described. We estimated MASH's economic burden in several regions of the world including the United States (U.S.), Germany, Spain, France, Italy, the United Kingdom (UK), Japan, Saudi Arabia, and Brazil over the next 2 decades. METHODS: A 1-year cycle Markov model projected MASH progression from 2021 to 2040, incorporating 2020 prevalent cases and annual incident cases (2021-2040). Transition probabilities were derived from the literature, calibrated using national estimates of prevalence rates for type 2 diabetes and obesity, and adjusted against observed incidences of decompensated cirrhosis, hepatocellular carcinoma, and liver transplants. MASH-related direct costs, productivity losses, and quality-of-life were updated annually based on projected disease stage. Future economic burdens were adjusted using country-specific inflation rates from the International Monetary Fund. RESULTS: MASH prevalence is projected to increase (2021-2040): United States (6.71%-7.41%), Germany (4.43%-4.97%), Spain (4.50%-5.38%), France (4.04%-4.50%), Italy (4.58%-5.37%), United Kingdom (4.75%-5.21%), Japan (3.67%-5.02%), Brazil (7.19%-7.52%), and Saudi Arabia (7.39%-7.50%). The prevalence of advanced MASH (F3- compensated cirrhosis, decompensated cirrhosis, hepatocellular carcinoma, and liver transplantations) is expected to increase by ≥20% in all countries. Direct annual medical costs are projected to more than double, increasing from $34.97 to $78.59 billion in the United States, $0.83 to $1.82 billion in Germany, $1.48 to $3.50 billion in Spain, $1.28 to $2.90 billion in France, $1.34 to $3.00 billion in Italy, $2.18 to $5.29 billion in the United Kingdom, $1.20 to $2.33 billion in Japan, $3.41 to $9.81 billion in Brazil, and $1.72 to $3.96 billion in Saudi Arabia. Work productivity losses are projected to more than double in most countries, and health-related quality of life will decline modestly as the burden of advanced disease increases CONCLUSIONS: Without intervention, the clinical, economic, and quality-of-life burden of MASH is projected to increase across most regions of the world. These findings highlight the urgent need for both national and global strategies to reduce the negative impact of MASH on individuals and society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Metabolic DiseasesFatty LiverGlobal Burden of DiseaseHealth Care CostsUnited StatesEuropeBrazilJapanSaudi ArabiaMarkov ChainsPrevalenceHumansIncidenceQuality of LifeFacilities and Services UtilizationForecastingInflation, EconomicMaleFemaleAdolescentYoung AdultAdultMiddle AgedAged

Stichwörter der Autor:innen

GBDGNCGNRGODTHRQLMASHMASLD

Autor:innen und Institutionen

  • The Global NASH/MASH Council, Washington, DC; Beatty Liver and Obesity Research Program, Inova Health System, Falls Church, Virginia; Center for Outcomes Research in Liver Diseases, Washington, DC. Electronic address: z…
  • The Global NASH/MASH Council, Washington, DC; Beatty Liver and Obesity Research Program, Inova Health System, Falls Church, Virginia; Center for Outcomes Research in Liver Diseases, Washington, DC.
  • The Global NASH/MASH Council, Washington, DC; Barcelona Institute for Global Health, Hospital Clínic, University of Barcelona, Barcelona, Spain.
  • The Global NASH/MASH Council, Washington, DC; Department of Surgery, Oncology and Gastroenterology, Padua University Hospital, Padua, Italy.
  • The Global NASH/MASH Council, Washington, DC; Loco Medical General Institute, Saga, Japan.
  • The Global NASH/MASH Council, Washington, DC; Department of Hepatology and Gastroenterology, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Förderung

  • Boehringer Ingelheim
  • Madrigal Pharmaceuticals Inc
  • Novo Nordisk AS

Zitieren

APA

Younossi, Z. M., Paik, J. M., Lazarus, J. V., Burra, P., Eguchi, Y., Tacke, F., Crespo, J., Villela-Nogueira, C. A., Brennan, P. N., Al-Omar, H. A., Romero-Gomez, M., Caussy, C., Pessoa, M. G., Cusi, K., Roden, M., Takahashi, H., Gastaldelli, A., Schattenberg, J. M., Oliveira, C. P., …, & Alqahtani, S. A. (2026). Projected Global Clinical, Humanistic, and Economic Impact of Metabolic Dysfunction-Associated Steatohepatitis (MASH): The Cost of Inaction Based on Data From Nine Countries. Clinical Gastroenterology and Hepatology, 24(4), 1016-1034. https://doi.org/10.1016/j.cgh.2025.09.002

Vancouver

Younossi ZM, Paik JM, Lazarus JV, Burra P, Eguchi Y, Tacke F, et al. Projected Global Clinical, Humanistic, and Economic Impact of Metabolic Dysfunction-Associated Steatohepatitis (MASH): The Cost of Inaction Based on Data From Nine Countries. Clinical Gastroenterology and Hepatology. 2026;24(4):1016-1034. doi:10.1016/j.cgh.2025.09.002

BibTeX
@article{Younossi2026,
  author = {Younossi, Zobair M and Paik, James M and Lazarus, Jeffrey V and Burra, Patrizia and Eguchi, Yuichiro and Tacke, Frank and Crespo, Javier and Villela-Nogueira, Cristiane A and Brennan, Paul N and Al-Omar, Hussain Abdulrahman and Romero-Gomez, Manuel and Caussy, Cyrielle and Pessoa, Mário Guimarães and Cusi, Kenneth and Roden, Michael and Takahashi, Hirokazu and Gastaldelli, Amalia and Schattenberg, Jörn M and Oliveira, Claudia Pinto and Kawaguchi, Takumi and Eguchi, Yuko and Boursier, Jerome and Abaalkhail, Faisal and Tomlinson, Jeremy W and Allen, Alina M and Wai-Sun Wong, Vincent and Bugianesi, Elisabetta and Newsome, Philip N and Calleja, Jose Luis and Brachowicz, Nicolai and Agirre-Garrido, Leire and Maya-Miles, Douglas and Razack, Habeeb I A and Mark, Henry E and Nader, Ariana and Battistella, Sara and Margier, Jennifer and Risso, Alessandra and Stepanova, Maria and Nader, Fatema and Henry, Linda and Castera, Laurent and Alqahtani, Saleh A},
  title = {Projected Global Clinical, Humanistic, and Economic Impact of Metabolic Dysfunction-Associated Steatohepatitis (MASH): The Cost of Inaction Based on Data From Nine Countries},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2026},
  volume = {24},
  number = {4},
  pages = {1016--1034},
  doi = {10.1016/j.cgh.2025.09.002}
}
Kostenlos starten →